Fact CheckerSign in

NCT07721675Not yet recruiting

Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma

Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment

Source: ClinicalTrials.gov · Last updated 23 Jul 2026

Brief summary (registry, in English)

The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
1300 (estimated)
First submitted
19 Jul 2026
Start date
1 Aug 2026
Primary completion date
31 Mar 2027
Lead sponsor
The Affiliated Hospital of Qingdao University
NCT number
NCT07721675

What you commit to

  • Study type: Observational
  • Planned participants: 1300
  • From 1 Aug 2026 to the primary completion date, 31 Mar 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Received preoperative neoadjuvant treatment.
  • Poor preservation of surgical paraffin specimens.
  • With concurrent malignancies other than high-grade serous ovarian carcinoma.

Other

  • Incomplete clinical information and survival follow-up data.

Who the study is looking for

  • Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.
  • Well-preserved surgical paraffin-embedded tumor specimens.
  • Complete clinical information and survival follow-up data.

Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.